Q&A: New Rules for Clinical Trials conducted in the EU
Recommendation

Thursday, 29 October 2026 9 .00 - 17.15 h
AI/ML-based Methods for Optimizing Pharmaceutical Research Processes
Following the positive vote in Parliament for the new Clinical Trial Regulation, the EU Commission has published a set of Q&As on clinical trials.
Here it is also discussed why the current legislation is being replaced and the main changes are summarised:
- The new authorisation procedure
- The simplified reporting procedures
- More rights for the Commission to conduct controls
In the new regulation, the concept of tacit agreement in the assessment phase of an application will be extended. According to the Q&A, this was needed "to avoid bottlenecks and delays in the procedure".
Related GMP News
23.09.2026FDA Publishes Draft Guidance on Potency Testing of Active Immunotherapy Products
27.08.2026EMA publishes Consolidated ICH E6(R3) Guideline
28.07.2026WHO publishes GCP Guidelines for Comment
09.07.2026Final ICH E6(R3) Annex 2
11.06.2026In-use Storage Time of Reconstituted Medicines
11.06.2026Pilot on Real-Time Clinical Trials


